USPTO Form Patent and Trade		Pepartment of Commerce DISCLOSURE STAT	EMENT	Attorney Docket No. 18396/2282		Serial No. 10/775,679				
				Applicant(s): Friedler, et al.						
				Filing Date: February 10, 2004			Group: Unknown			
U.S. PAT	ENT DO	OCUMENTS	· · · · · · · · · · · · · · · · · · ·							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Subclass Filing Date (if appropriate)			
FOREIGN PATENT DOCUMENTS			Dublingin	T	Class		Translation			
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass		T		
AR	1.	WO97/37645	October 16, 1997	wo	A61K	31/135	YES	МО		
	2.	WO99/58566	Nov 18, 1999	wo	C07K	14/47				
	3.	WO00/32175	June 8, 2000	wo	A61K	31/00				
	4.	DE100 43 456 A1	March 14, 2002	DE ·	A61K	31/505	See 4A			
	4A.	US2003/0199446 A1	October 23, 2003	US .	A61K	38/17				
OTHER I		ENTS (including Aut)	or, Title, Date, Pertin	ent Pages, etc.)		<u></u>				
AR	5.	MENTS (including Author, Title, Date, Pertinent Pages, etc.) Foster, et al., "Pharmacological Rescue of Mutant p53 Conformation and Function", Science, V. 286, December 24, 1999, Pages 2507-2510.								
	6.	Gamble, et al., "Evidence that Immunological Variants of p53 Represent Alternative Protein Conformations", Virology (1988), V. 162, Pages 452-458.								
	7.	Naumovski, et al., "The p53-Binding Protein 53BP2 Also Interacts with Bc12 and Impedes Cell Cycle Progression at G ₂ /M", <i>Molecular and Cellular Biology</i> , V. 16, July 7, 1996, Pages 3884-3892.								
8. Nikolova, et al, "Mechanism of Rescue of Common p53 Cancer Mutations by Sec Mutations", <i>The Embo Journal</i> (2000), V. 19, No. 3, Pages 370-378.							d-Site Supp	ressor		
	9. Selivanova, et al., "Reactivation of Mutant p53 Through Interaction of a C-Terminal Peptide with the Core Domain", Molecular and Cellular Biology, V. 19, No. 5, May 1999, Pages 3395-3402.									
V	10.		ional Search Report (I							
EXAMIN	er p	tomes B. Re	soke		DATE CO	DATE CONSIDERED 3/16/2005				
EXAMINER:	initial if refere	nce considered, whether or not citation	in is in conformance with MPEP 609). Draw line through citation if not	in conformance an	d not considered.	Include copy of thi	is form wi		

SEP 0 7 2004

USPTO Form 1		S. Department of Commerce		Attorney Docket No.		Serial No.						
INFORMATION DISCLOSURE STATEMENT				18396/2282 10/			10/775,679					
				Applicant(s):. Friedler, et al.								
	· · · · · · · · · · · · · · · · · · ·			Filing Date: February 10, 2004			Groups Not yet assigned 1653					
U.S. PATENT DOCUMENTS												
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)					
FOREIGN PATENT DOCUMENTS												
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Transla					
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)												
AR	1.	Cho, et al., "Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations", Science (1994), V. 265, Pages 346-355.										
	2.	Selivanova, et al., "Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain", Nature Medicine (1997), V. 3, Pages 632-638.										
	3.	Bullock, et al., "Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy", Oncogene (2000), V. 19, Pages 1245-1256.										
	4.	Abarzua, et al., "Restoration of the transcription activation function to mutant p53 in human cancer cells", Oncogene (1996), V. 13, Pages 2477-2482.										
	5.	Hainaut, et al., "p53 and human cancer: the first ten thousand mutations", Advances in Cancer Research (2000), V. 77, Pages 81-137.										
	6.	Hupp, et al., "Small peptides activate the latent sequence-specific DNA binding function of p53", Cell (1995), V. 83, Pages 237-245.										
	7.	Hupp, et al., "Strategies for manipulating the p53 pathway in the treatment of human cancer", Biochemical Journal (2000), V. 352, Pages 1-17.										
,	8.	Sigal, et al., "Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome", Cancer Research (2000), V. 60, Pages 6788-6793.										
1	9.	Selivanova, et al., "Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain", Molecular and Cellular Biology (1999), V. 19, Pages 3395-3402.										
EXAMINER Agnes B. Rooke DATE CONSIDERED 3/16/2005												
*EXAMINER:	Initial if refere	nce considered, whether or not citation	n is in conformance with MPEP 609	. Draw line through citation if not in	conformance an	d not considered.	Include copy of thi	s form with				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

^{**}Copies of references not provided at the time of this submission.